152 related articles for article (PubMed ID: 10096553)
1. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor.
Maekawa R; Maki H; Yoshida H; Hojo K; Tanaka H; Wada T; Uchida N; Takeda Y; Kasai H; Okamoto H; Tsuzuki H; Kambayashi Y; Watanabe F; Kawada K; Toda K; Ohtani M; Sugita K; Yoshioka T
Cancer Res; 1999 Mar; 59(6):1231-5. PubMed ID: 10096553
[TBL] [Abstract][Full Text] [Related]
2. [Antiangiogenic and antitumor effect of BPHA, an orally-active matrix metalloproteinase inhibitor, in in vivo murine and human tumor model].
Maki H; Maekawa R; Yoshida H; Hojo K; Uchida N; Wada T; Tanaka H; Takeda Y; Matsumoto M; Yamada H; Nishitani Y; Shono K; Kasai H; Sato S; Okamoto H; Hayashi R; Tamura Y; Tsuzuki H; Watanabe F; Sugita K; Yoshioka T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1599-606. PubMed ID: 10553417
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography.
Ikeda M; Maekawa R; Tanaka H; Matsumoto M; Takeda Y; Tamura Y; Nemori R; Yoshioka T
Clin Cancer Res; 2000 Aug; 6(8):3290-6. PubMed ID: 10955815
[TBL] [Abstract][Full Text] [Related]
4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
5. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
6. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.
Lozonschi L; Sunamura M; Kobari M; Egawa S; Ding L; Matsuno S
Cancer Res; 1999 Mar; 59(6):1252-8. PubMed ID: 10096556
[TBL] [Abstract][Full Text] [Related]
7. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice.
Dabrowska A; Giermasz A; Marczak M; Gołab J; Jakóbisiak M
Anticancer Res; 2000; 20(1A):391-4. PubMed ID: 10769685
[TBL] [Abstract][Full Text] [Related]
8. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.
Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S
Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.
Naglich JG; Jure-Kunkel M; Gupta E; Fargnoli J; Henderson AJ; Lewin AC; Talbott R; Baxter A; Bird J; Savopoulos R; Wills R; Kramer RA; Trail PA
Cancer Res; 2001 Dec; 61(23):8480-5. PubMed ID: 11731431
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting with a selective gelatinase inhibitor.
Koivunen E; Arap W; Valtanen H; Rainisalo A; Medina OP; Heikkilä P; Kantor C; Gahmberg CG; Salo T; Konttinen YT; Sorsa T; Ruoslahti E; Pasqualini R
Nat Biotechnol; 1999 Aug; 17(8):768-74. PubMed ID: 10429241
[TBL] [Abstract][Full Text] [Related]
11. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
12. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
Tamura Y; Watanabe F; Nakatani T; Yasui K; Fuji M; Komurasaki T; Tsuzuki H; Maekawa R; Yoshioka T; Kawada K; Sugita K; Ohtani M
J Med Chem; 1998 Feb; 41(4):640-9. PubMed ID: 9484512
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of invasion and lymph node metastasis of gastrointestinal cancer cells by R-94138, a matrix metalloproteinase inhibitor.
Matsuoka T; Yashiro M; Sawada T; Ishikawa T; Ohira M; Chung KH
Anticancer Res; 2000; 20(6B):4331-8. PubMed ID: 11205267
[TBL] [Abstract][Full Text] [Related]
15. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo.
Gutman M; Szold A; Ravid A; Lazauskas T; Merimsky O; Klausner JM
Anticancer Res; 1996; 16(6B):3673-7. PubMed ID: 9042240
[TBL] [Abstract][Full Text] [Related]
16. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
17. Carbamoylphosphonate matrix metalloproteinase inhibitors 3: in vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis.
Reich R; Katz Y; Hadar R; Breuer E
Clin Cancer Res; 2005 May; 11(10):3925-9. PubMed ID: 15897594
[TBL] [Abstract][Full Text] [Related]
18. (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis.
Yamakawa S; Asai T; Uchida T; Matsukawa M; Akizawa T; Oku N
Cancer Lett; 2004 Jul; 210(1):47-55. PubMed ID: 15172120
[TBL] [Abstract][Full Text] [Related]
19. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
Shalinsky DR; Brekken J; Zou H; McDermott CD; Forsyth P; Edwards D; Margosiak S; Bender S; Truitt G; Wood A; Varki NM; Appelt K
Ann N Y Acad Sci; 1999 Jun; 878():236-70. PubMed ID: 10415735
[TBL] [Abstract][Full Text] [Related]
20. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells.
Nyormoi O; Mills L; Bar-Eli M
Cell Death Differ; 2003 May; 10(5):558-69. PubMed ID: 12728254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
